Cellect Biotechnology Ltd., a developer of a novel stem cell production technology, has received a Notice of Allowance from the Korean Intellectual Property Office for its patent titled, "Devices and Methods for Selecting Apoptosis-Signaling Resistant Cells, and Uses Thereof". This patent, recently granted to Cellect in Europe, addresses the Company's ApoTainer device which is used in conjunction with its platform ApoGraft technology.

"As we expand the number of stem cell industry collaborations for Cellect worldwide, our international patent assets and protections become increasingly important. In the past six weeks alone, we entered into collaborations with companies in Germany, Switzerland and Korea. Working with industry partners to improve the safety and efficacy of stem cells and expanding regenerative medicine's wide scale availability and affordability are cornerstones of Cellect's strategy. Our growing IP estate supports this purpose," stated Cellect CEO Dr. Shai Yarkoni.

The patent addresses Cellect's devices and methods for specifically selecting desired stem cells from a heterogeneous cell population for use in a range of medical indications. Through negative selection, Cellect's technology identifies mature cells that can be harmful to the recipient and selectively eliminates those cells through apoptosis (cell death). Cellect's patented technology is designed to produce safe and ample quantities of stem cells ready for dosing in patients in a wide range of disease states from oncology to auto-immune diseases. The latest patent covers claims including Cellect's method for preventing graft vs. host disease (GvHD) while retaining potent anti-cancer graft vs. tumor (GvT) activity using the ApoTainer device.

-----------------------------------------------------------------------------
Editor's Note:

To apply for becoming a contributor of en-CPhI.cn,

welcome to send your CV and sample works to us,

Email: Julia.Zhang@ubmsinoexpo.com.